Following from a subgroup analysis of the CAMILLA trial (NCT03539822) of cabozantinib, a tyrosine kinase inhibitor (TKI), plus durvalumab, cabozantinib demonstrated encouraging results in patients with wild type colorectal cancer (CRC). Anwaar Saeed, MD, University of Kansas Cancer Center, Kansas City, KS, discusses the trial rationale and trial design of the Phase III STELLAR-303 trial (NCT05425940), which assessed XL092 in pre-treated patients with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic CRC. Patients were randomized to receive XL092, a next-generation TKI, with either atezolizumab or regorafenib. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.